Skip to main content
. 2024 Sep 30;38(6):755–767. doi: 10.1007/s40259-024-00671-4

Fig. 5.

Fig. 5

Cumulative number of new active lesions over 48 weeks for biosimilar natalizumab (biosim-NTZ) versus reference natalizumab (ref-NTZ) groups by primary randomization in the Antelope study. Hemmer et al. [50]. Reprinted by permission of JAMA Network